GET DAILY SIGNALSImmunic (IMUX) Readies Q3 2026 Earnings as Clinical Data Looms
Key Takeaways
- Immunic, Inc. (IMUX), a clinical-stage biopharmaceutical company, is expected to report third quarter 2026 results on or around November 12, 2026.
- Wall Street consensus calls for a net loss of roughly -$0.94 per share, versus -$1.30 per share in the same period a year ago; no revenue is expected because the company has no marketed products.
- In the prior quarter (Q2 2026), Immunic reported EPS of -$0.80, beating the -$1.16 consensus estimate by $0.36.
- Investor focus is fixed on the Phase 3 ENSURE trial of lead candidate vidofludimus calcium in relapsing multiple sclerosis (MS), with top-line data expected later in 2026.
- Research and development (R&D) spending and the company's cash runway will be closely scrutinized following recent private placement financings.
Why This Earnings Report Matters
Immunic is a clinical-stage biopharmaceutical company developing novel oral therapies for chronic inflammatory, autoimmune, and neurodegenerative diseases. Because it has no approved products, its quarterly earnings are driven almost entirely by research and development (R&D) spending, and reported revenue is typically zero. That makes each report less about sales and more about two questions: how quickly the company is burning cash, and whether it remains on track to reach its clinical milestones. With lead candidate vidofludimus calcium (IMU-838) approaching a pivotal Phase 3 data readout in multiple sclerosis, the Q3 update carries outsized weight for investors weighing the company's balance sheet against its upcoming catalysts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
For the third quarter ended September 30, 2026, analysts expect Immunic to post a net loss of approximately -$0.94 per share, according to consensus estimates. That compares with a loss of -$1.30 per share reported in the third quarter of 2025, when the company recorded a net loss of roughly $25.58 million. Consensus revenue is effectively zero, consistent with a pre-commercial biotech that generates no product sales.
Historically, Immunic has not always tracked consensus closely. In the most recent quarter (Q2 2026), the company reported EPS of -$0.80, beating the -$1.16 estimate by $0.36 and beating consensus in three of its last eight quarters. Investors will therefore watch both the headline loss and the underlying drivers, particularly R&D expense levels tied to late-stage trials of vidofludimus calcium, along with any updates on cash position and future financing plans. From what I see, this pattern of beats and misses adds another layer to how the numbers might be interpreted.
Market Reaction and Investor Sentiment
Sentiment heading into this report is dominated by clinical rather than financial news. Immunic has seen substantial share-price volatility in recent months, driven by financing announcements, multiple sclerosis data updates, and a decision to transfer its listing to the Nasdaq Capital Market. As a pre-revenue company, the market is likely to react less to the earnings per share (EPS) figure itself and more to management's commentary on trial timelines and cash runway.
Key risks to watch include a larger-than-expected quarterly loss, any indication that R&D spending is accelerating faster than anticipated, or any change in the timing of the Phase 3 ENSURE trial readout. Because the stock has shown high beta around data events, even minor shifts in guidance or timeline language could amplify the post-print move. I’m watching this closely as the earnings date approaches.
Forward Outlook and Key Factors to Monitor
The most important near-term catalyst is the Phase 3 ENSURE trial of vidofludimus calcium in relapsing multiple sclerosis, with top-line data expected by the end of 2026. A positive readout would mark a major step toward potential regulatory filings and a first commercial product, while a negative or inconclusive result would reset the investment thesis.
Investors should also monitor the company's plans to initiate an additional Phase 3 program in progressive multiple sclerosis, which management has signaled for later in 2026. Beyond the lead asset, early-stage programs such as IMU-381 and IMU-856 provide optionality but remain farther from value inflection.
On the financial side, cash runway remains the central question. Immunic recently completed private placement financings intended to fund operations through its key data milestones, but the precise runway will depend on the pace of R&D spending. Watch for management's cash guidance, any forward-looking commentary on additional capital needs, and updates on cost discipline as the pivotal readouts approach.
AI Tools in My Research Workflow
In my view, Tickeron’s AI Screener has become a useful part of how I prepare for earnings seasons like this one. It lets me quickly filter for stocks with similar setups or momentum signals, which helps put a name like Immunic into broader context without spending hours on manual screens. The tool surfaces ideas based on technical patterns, fundamentals, and AI-driven signals, and I find it especially handy when tracking pre-revenue biotechs ahead of clinical updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMUX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for IMUX turned positive on October 15, 2026. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMUX's RSI Indicator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +2.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in 212 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 53 cases where IMUX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMUX as a result. In 71 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The 50-day moving average for IMUX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMUX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.829) is normal, around the industry mean (3.498). P/E Ratio (-2.183) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. IMUX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases
Industry Biotechnology
Advertisement